Ankylosing Spondylitis Market Expected to Reach US$ 9,020 Million by 2033 | IMARC Group

IMARC Group has recently released a report titled “Ankylosing Spondylitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033” that presents a comprehensive assessment of the ankylosing spondylitis market size, latest trends, and growth forecast. The report provides an overview of the market trends, growth prospects, investment opportunities, and industry prospects, as well as an analysis of the disease overview, market scenario, and growth trends. In addition, the report offers competitor analysis, regional analysis, and recent advancements in the seven major markets (7MM). The report also highlights key segments and market drivers, as well as challenges faced by industry players.

How big is the market for ankylosing spondylitis?

According to IMARC Group, in 2022, the total value of the seven major markets (7MM) for ankylosing spondylitis amounted to US$ 4,466 Million. Looking forward, these markets are anticipated to reach US$ 9,020 Million by 2033, at a growth rate (CAGR) of 6.56% from 2023-2033.

What is ankylosing spondylitis?

Ankylosing spondylitis (AS) refers to a chronic inflammatory disease that mainly affects the joints of the spine, which leads to stiffness and pain. The symptoms of this condition begin in the sacroiliac joints and can gradually lead to the fusion of the spinal bones, which further results in the loss of mobility and flexibility in the spine. Moreover, AS is classified as a type of inflammatory arthritis that can persist throughout a person’s lifetime. The diagnosis of AS can be confirmed if an X-ray shows swelling on the sacroiliac joints, and the individual must have at least 1 of the following conditions: a minimum of three months of continuous lower back pain, limited chest expansion, or limited movement in the lower back.

Request a Free Sample Report: https://www.imarcgroup.com/ankylosing-spondylitis-market/requestsample

What are the key drivers and trends in the ankylosing spondylitis market?

The growing prevalence of inflammatory arthritis along with the escalating demand for effective medications to treat this condition is primarily driving the ankylosing spondylitis market. Besides this, the increasing awareness regarding the importance of early diagnosis and treatment of AS is also catalyzing the market growth. Additionally, the inflating adoption of biologic medications, which are more effective in treating ankylosing spondylitis than conventional non-biologic drugs, is creating a positive outlook for the market.

In line with this, the growing popularity of disease-modifying anti-rheumatic drugs (DMARDs), as they help slow the disease progression, is also augmenting the market growth. Moreover, the rising preferences for physical rehabilitation and therapies to maintain mobility and prevent spinal fusion are anticipated to propel the growth of the ankylosing spondylitis market in the coming years.

What is included in the report segmentation?

The report covers the following aspects:

Report Period:

• Base Year: 2022
• Historical Period: 2017-2022
• Market Forecast: 2023-2033

Countries Included:

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the ankylosing spondylitis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the ankylosing spondylitis market
• Reimbursement scenario in the market

In-market and pipeline drugs

• In-Market Drugs
• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Regulatory Status

Ask an Analyst for Report Customization with TOC & List of figures: https://www.imarcgroup.com/request?type=report&id=6766&flag=C

Key Questions Answered in this Report:

• How has the ankylosing spondylitis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2022 and how are they expected to perform till 2033?
• What was the country-wise size of the ankylosing spondylitis market across the seven major markets in 2022 and what will it look like in 2033?
• What is the growth rate of the ankylosing spondylitis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Browse the Latest Research Report:

Graft vs Host Disease Market Report 2023-2033

Non-Small Cell Lung Cancer (NSCLC) Market Report 2023-2033

Dystrophic Epidermolysis Bullosa Market Report 2023-2033

Non-alcoholic Fatty Liver Disease (NAFLD) Market Report 2023-2033

This report will help you with:

• Identifying the key players operating in the ankylosing spondylitis market and understanding their market dominance.
• Knowing the essential factors to consider when evaluating a ankylosing spondylitis market, aiding in informed decision-making.
• Understanding the driving forces behind the ankylosing spondylitis market, enabling businesses to stay ahead of emerging trends and capitalize on opportunities.
• Examining the changing market behavior over time and strategically assessing competition, facilitating effective benchmarking and strategic planning.

About Us: –

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group

134 N 4th St.

Brooklyn, NY 11249, USA

Email: Sales@imarcgroup.com

Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800